Record mula sa primary source
MateryalTinanggap ang aplikasyon
Voyager Therapeutics: Inaprubahan ng FDA ang IND para sa VY1706 na tau-silencing gene therapy
Inaprubahan ng FDA ang IND para sa VY1706, na nagpapahintulot sa kumpanya na magpatuloy sa unang pagsubok sa tao, multi-site, open-label, dose-escalation trial sa mga pasyenteng may maagang AD na may kumpirmadong tau pathology. Ang dosing ay binalak na simulan sa ikalawang kalahati ng 2026, na may hanggang 18 kalahok sa tatlong cohorts na tumatanggap ng isang intravenous dose.
Mahahalagang fact
- Na-file
- Hun 1, 2026, 12:00 PM
- Kaganapan
- Tinanggap ang aplikasyon
- Direksyon
- Positibo
- Kumpanya
VYGRVoyager Therapeutics- Asset
- VY1706
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
false 0001640266 0001640266 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 75 Hayden Avenue Lexington , Massachusetts 02421 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code ( 857 ) 259-5340 Not Applicable (Former name, former address and